FDA Approves New Agent for Nerve Pain From Rare Inherited Disease
(MedPage Today) -- Eplontersen (Wainua) was approved by the FDA to treat polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTR) in adults, Ionis Pharmaceuticals and AstraZeneca announced on Thursday.
Hereditary ATTR...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Amyloidosis | AstraZeneca | International Medicine & Public Health | Pain